癌免疫細胞療法と体外循環治療(<特集>細胞治療とアフェレシス)

概要

論文の詳細を見る
Immune-cell therapy for solid cancer remains challenging. Adoptive immunotherapy with cultured killer T lymphocytes and interleukin-2 has been actively tried since the middle of the 1980's. However, the main stream has become dendritic cell-based, tumor-specific active immunotherapy since the latter half of the 1990's. Despite much effort, immune-cell therapy has not yet achieved an adequate anti-tumor effect comparable with that of chemotherapy. In addition, there are a lot of problems with immune-cell therapy, which needs in vitro cell processing under the observance of good manufacturing practice (GMP). It is labor- and resource-consuming, and cannot avoid the risk of microbial contamination. In view of these problems, we started research on a new immunotherapy technique with direct hemoperfusion. We have succeeded in developing a direct hemoperfusion column for cancer immunotherapy which consists of extra-fine synthetic fibers removing immunosuppressive cytokines from the peripheral blood of advanced cancer patients. In addition, we are developing another column consisting of fibers immobilized with lipoteichoic acid that can activate immune cells widely. Direct hemoperfusion with these columns can be a novel strategy of cancer immunotherapy and is expected to achieve synergistic effects with immune-cell therapy or chemotherapy.
日本アフェレシス学会の論文
2007-05-31